CA-215 is a tumour-associated antigen used as a biomarker in certain cancers. It belongs to the family of mucin-like antigens and is elevated in several malignancies including ovarian, cervical, endometrial, and other gynaecological cancers, as well as gastrointestinal cancers. It is typically measured as a complement to other tumour markers rather than as a standalone diagnostic test.
Like most tumour markers, CA-215 has limited utility as a primary screening tool due to overlap with benign conditions. Its greatest clinical value is in monitoring treatment response and detecting disease recurrence in patients with known cancers that produce this antigen. Serial measurements over time provide more clinically meaningful information than any single result.
FAQs
What cancers are associated with elevated CA-215?
CA-215 is associated with gynaecological cancers including ovarian, cervical, and endometrial cancer, as well as gastrointestinal malignancies. It is often used as part of a panel with other markers rather than as a standalone test.
Is an elevated CA-215 always due to cancer?
No — benign gynaecological and inflammatory conditions can mildly elevate CA-215. An elevated result requires clinical correlation, imaging, and specialist review before any conclusions are drawn.
How is CA-215 used in cancer monitoring?
In patients with known CA-215-producing cancers, serial measurements are used to assess treatment response (levels should fall with effective treatment) and to detect recurrence during surveillance (rising levels precede clinical recurrence).
Should CA-215 be used for cancer screening in healthy people?
CA-215 is not recommended as a standalone routine cancer screening test. Like most tumour markers, it has insufficient specificity for population screening. It is most clinically useful in people with known cancer or a high clinical suspicion of malignancy.
